Chatham Capital Group’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $208K | Buy |
+939
| New | +$205K | 0.03% | 202 |
|
|
2026
Q2 | – | Sell |
-1,100
| Closed | -$247K | – | 205 |
|
|
2026
Q1 | $247K | Hold |
1,100
| – | – | 0.04% | 191 |
|
|
2025
Q4 | $265K | Hold |
1,100
| – | – | 0.04% | 190 |
|
|
2025
Q3 | $301K | Hold |
1,100
| – | – | 0.04% | 184 |
|
|
2025
Q2 | $284K | Sell |
1,100
-150
| -12% | -$35.8K | 0.04% | 185 |
|
|
2025
Q1 | $280K | Hold |
1,250
| – | – | 0.05% | 182 |
|
|
2024
Q4 | $286K | Hold |
1,250
| – | – | 0.05% | 180 |
|
|
2024
Q3 | $305K | Hold |
1,250
| – | – | 0.05% | 173 |
|
|
2024
Q2 | $239K | Hold |
1,250
| – | – | 0.04% | 180 |
|
|
2024
Q1 | $248K | Hold |
1,250
| – | – | 0.05% | 179 |
|
|
2023
Q4 | $215K | Buy |
+1,250
| New | +$192K | 0.04% | 178 |
|
|
2023
Q3 | – | Sell |
-1,250
| Closed | -$273K | – | 190 |
|
|
2023
Q2 | $273K | Hold |
1,250
| – | – | 0.06% | 172 |
|
|
2023
Q1 | $274K | Hold |
1,250
| – | – | 0.06% | 170 |
|
|
2022
Q4 | $260K | Hold |
1,250
| – | – | 0.06% | 171 |
|
|
2022
Q3 | $273K | Hold |
1,250
| – | – | 0.07% | 161 |
|
|
2022
Q2 | $262K | Hold |
1,250
| – | – | 0.06% | 168 |
|
|
2022
Q1 | $303K | Sell |
1,250
-740
| -37% | -$179K | 0.06% | 160 |
|
|
2021
Q4 | $518K | Hold |
1,990
| – | – | 0.09% | 145 |
|
|
2021
Q3 | $524K | Hold |
1,990
| – | – | 0.1% | 142 |
|
|
2021
Q2 | $491K | Hold |
1,990
| – | – | 0.09% | 141 |
|
|
2021
Q1 | $386K | Hold |
1,990
| – | – | 0.08% | 145 |
|
|
2020
Q4 | $423K | Hold |
1,990
| – | – | 0.1% | 135 |
|
|
2020
Q3 | $341K | Hold |
1,990
| – | – | 0.08% | 131 |
|
|
2020
Q2 | $382K | Sell |
1,990
-350
| -15% | -$57.3K | 0.1% | 126 |
|
|
2020
Q1 | $345K | Hold |
2,340
| – | – | 0.1% | 131 |
|
|
2019
Q4 | $363K | Hold |
2,340
| – | – | 0.09% | 137 |
|
|
2019
Q3 | $316K | Hold |
2,340
| – | – | 0.08% | 137 |
|
|
2019
Q2 | $286K | Hold |
2,340
| – | – | 0.07% | 145 |
|
|
2019
Q1 | $243K | Hold |
2,340
| – | – | 0.06% | 147 |
|
|
2018
Q4 | $266K | Hold |
2,340
| – | – | 0.07% | 141 |
|
|
2018
Q3 | $270K | Hold |
2,340
| – | – | 0.07% | 133 |
|
|
2018
Q2 | $242K | Hold |
2,340
| – | – | 0.06% | 139 |
|
|
2018
Q1 | $230K | Buy |
+2,340
| New | +$221K | 0.06% | 137 |
|
|
2017
Q2 | – | Sell |
-21,405
| Closed | -$1.54M | – | 155 |
|
|
2017
Q1 | $1.54M | Sell |
21,405
-2,040
| -9% | -$141K | 0.43% | 48 |
|
|
2016
Q4 | $1.46M | Buy |
23,445
+4,400
| +23% | +$269K | 0.42% | 55 |
|
|
2016
Q3 | $1.23M | Sell |
19,045
-750
| -4% | -$49.9K | 0.39% | 50 |
|
|
2016
Q2 | $1.25M | Hold |
19,795
| – | – | 0.39% | 49 |
|
|
2016
Q1 | $1.14M | Sell |
19,795
-400
| -2% | -$22.6K | 0.36% | 54 |
|
|
2015
Q4 | $1.08M | Hold |
20,195
| – | – | 0.35% | 60 |
|
|
2015
Q3 | $1.03M | Sell |
20,195
-250
| -1% | -$13.5K | 0.35% | 59 |
|
|
2015
Q2 | $1.15M | Hold |
20,445
| – | – | 0.32% | 63 |
|
|
2015
Q1 | $1.47M | Buy |
20,445
+550
| +3% | +$35.7K | 0.43% | 50 |
|
|
2014
Q4 | $1.12M | Hold |
19,895
| – | – | 0.33% | 60 |
|
|
2014
Q3 | $980K | Buy |
19,895
+200
| +1% | +$10.2K | 0.3% | 68 |
|
|
2014
Q2 | $997K | Hold |
19,695
| – | – | 0.39% | 57 |
|
|
2014
Q1 | $880K | Hold |
19,695
| – | – | 0.36% | 58 |
|
|
2013
Q4 | $927K | Hold |
19,695
| – | – | 0.39% | 59 |
|
|
2013
Q3 | $1.04M | Hold |
19,695
| – | – | 0.47% | 47 |
|
|
2013
Q2 | $889K | Buy |
+19,695
| New | +$934K | 0.43% | 49 |
|
Other funds holding RMD
Chatham Capital Group's RMD Position: Q3 2026 in Review
Chatham Capital Group opened a new position in ResMed (RMD) in Q3 2026: 939 shares worth $208K. The stake represents 0.03% of the portfolio and ranks #202 among its holdings. This is a return to the name: Chatham Capital Group previously reported a position in RMD as recently as Q1 2026.
Chatham Capital Group first reported a position in RMD in Q2 2013 and has held it in 49 quarters since. The position peaked at $1.54M in Q1 2017. 886 funds tracked by Wall St. Rank hold RMD as of Q3 2026.
- Chatham Capital Group held 939 shares of ResMed worth $208K as of Q3 2026.
- ResMed was a new Chatham Capital Group position in Q3 2026.
- ResMed made up 0.03% of Chatham Capital Group's portfolio in Q3 2026, its #202 holding.
- Chatham Capital Group first reported a position in ResMed in Q2 2013 and has held it in 49 quarters since.
- Chatham Capital Group's ResMed position peaked at $1.54M in Q1 2017.
- 886 funds tracked by Wall St. Rank held ResMed as of Q3 2026.
Based on Chatham Capital Group's 13F filing for Q3 2026, filed 16 Oct 2026.